Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
5 hedge funds and large institutions have $136K invested in Timber Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 5 closing their positions.
49% more capital invested
Capital invested by funds: $91K → $136K (+$45K)
29% less funds holding
Funds holding: 7 → 5 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$188K |
| 2 |
Morgan Stanley
New York
|
+$10.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.29K |
| 4 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$349 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$175 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$37K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$7K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $117K | +$188K | +1,074 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $10K | +$6.29K | +36 | +62% |
|
|
3
Morgan Stanley
New York
| $7K | +$10.5K | +60 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $2K | +$175 | +1 | +6% |
|
|
5
Barclays
London,
United Kingdom
| – | -$37K | -203 | Closed |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| – | -$23K | -125 | Closed |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| – | -$8K | -45 | Closed |
|
|
8
Northern Trust
Chicago,
Illinois
| – | -$7K | -37 | Closed |
|
|
9
Victory Capital Management
San Antonio,
Texas
| – | -$2K | -8 | Closed |
|
|
PFO
10
Pathstone Family Office
Englewood,
New Jersey
| – | +$349 | +2 | New |
|
TMBR Hedge Fund Activity: Q2 2020 in Review
5 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2020, worth a combined $136K — up 49% from $91K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TMBR and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $188K. The largest seller was Barclays, exiting entirely with an estimated $37K sold.
- 5 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2020, down from 7 in Q1 2020.
- Funds reported $136K of Timber Pharmaceuticals, Inc. stock for Q2 2020, up 49% quarter-over-quarter.
- 3 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2020 and 5 closed out, a net change of -2 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2020 was Deutsche Bank, an estimated $188K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2020 was Barclays, an estimated $37K sold.
Based on aggregated 13F filings for Q2 2020.